undamentalytics Newsletter
Sign in

Therapeuticsmd, Inc. income statement

In fiscal 2025, Therapeuticsmd, Inc. reported revenue of $3.0m, up 71.6% on the year before, operating income of −$4.4m (a -145.3% margin) and net income of −$569,000, or −$0.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue249152019171650653701233
Cost of revenue—————43361611————
Gross profit127111615141343491691———
Research and development0414437254342720107—————
Selling, general and administrative6141922295158116174193——95——
Selling and marketing——————————108—————
General and administrative——————————8157——77
Operating income−5−16−26−54−85−90−78−130−151−156−801−9−6−4−4
Interest expense0221———51729330000—
Income before tax−13−35−28−54−85−90−77−133−176−184−791−8−2−1−0
Income tax————————————−0−0——
Net income−13−35−28−54−85−90−77−133−176−184−172112−10−2−1−0
Diluted EPS−$0.21−$0.38−$0.22−$0.36−$0.49−$0.46−$0.37−$0.59−$0.72−$0.67−$21.66$11.96−$0.99−$0.19−$0.05—
Diluted shares (average)1m2m3m3m3m4m4m5m5m6m8m9m10m12m12m—
EBITDA−5−16−26−54−85−90−77−130−150−151−792−8−6−4−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EYPT vs TXMDCPHI vs TXMDNTRB vs TXMD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Therapeuticsmd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Therapeuticsmd, Inc.